Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 15/20 | 0.42 |
| ▸ | F7 | P08709 | 14/20 | 0.42 |
| ▸ | F10 | P00742 | 13/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11024124 | 0.91 | F11 (0.43) | F11F7F10SCN9A | |
| SCHEMBL11940913 | 0.89 | SCN9A (0.37) | F11F7F10SCN9ASCN5A | |
| SCHEMBL11940899 | 0.86 | F11 (0.42) | F11F7F10SCN9A | |
| SCHEMBL11940891 | 0.85 | SCN9A (0.42) | F11F7F10SCN9ASCN5A | |
| SCHEMBL11023687 | 0.84 | F11 (0.50) | F11F7F10 | |
| SCHEMBL11025278 | 0.83 | F11 (0.51) | F11F7F10 | |
| SCHEMBL11024582 | 0.83 | F7 (0.43) | F11F7F10SCN9ASCN5A | |
| SCHEMBL11940893 | 0.83 | F11 (0.38) | F11F7F10SCN9ASCN5A | |
| SCHEMBL11940892 | 0.81 | F11 (0.43) | F11F7F10SCN9ASCN5A | |
| SCHEMBL11940896 | 0.81 | F11 (0.38) | F11F7F10SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | F11 2989/4885F7 2297/4885F10 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.